{"text": ["The", "best", "companies", "for", "employees", "in", "2019"], "created_at": "2019-04-22 21:50:27"}
{"text": ["Eli", "Lilly", "Falls", "Despite", "Positive", "Phase", "3", "Results", "From", "Taltz", "Study"], "created_at": "2019-04-22 15:13:00"}
{"text": ["Update:", "Eli", "Lilly", "(NYSE:LLY)", "Stock", "Gained", "97%", "In", "The", "Last", "Five", "Years"], "created_at": "2019-04-22 15:12:00"}
{"text": ["Eli", "Lilly-Pfizer's", "Non-Opioid", "Painkiller", "Faces", "Safety,", "Efficacy", "Concerns"], "created_at": "2019-04-22 14:24:22"}
{"text": ["Health", "Care", "Sector", "Update", "for", "04/22/2019:", "ISRG,", "AXGN,", "LLY,", "JNJ,", "PFE,", "ABT,", "MRK,", "AMGN"], "created_at": "2019-04-22 13:46:47"}
{"text": ["Health", "Care", "Sector", "Update", "for", "04/22/2019:", "ISRG,", "AXGN,", "LLY,", "JNJ,", "PFE,", "ABT,", "MRK,", "AMGN"], "created_at": "2019-04-22 13:46:47"}
{"text": ["Eli", "Lilly", "stock", "down", "3.4%", "despite", "positive", "Phase", "3", "findings", "for", "Taltz"], "created_at": "2019-04-22 12:00:00"}
{"text": ["Lilly", "Announces", "Positive", "Top-Line", "Results", "for", "COAST-X,", "a", "52-Week", "Placebo-Controlled", "Study", "of", "Taltz\u00ae", "(ixekizumab)", "in", "Patients", "with", "Non-Radiographic", "Axial", "Spondyloarthritis"], "created_at": "2019-04-22 10:45:00"}
{"text": ["Lilly", "and", "Avidity", "Biosciences", "Announce", "Licensing", "and", "Research", "Collaboration"], "created_at": "2019-04-22 10:30:00"}
